June 15, 2021
Sonoran Biosciences Reports Positive Results for Postoperative Pain Program
TEMPE, Ariz., Jun 15, 2021 — Sonoran Biosciences (“Sonoran” or the “Company”, a preclinical-stage pharmaceutical company developing innovative hospital based products for the treatment of postoperative pain and surgical site infection, announced today that the Company’s product SBG004 (bupivacaine extended-release gel-forming solution) has demonstrated analgesia lasting up to 120 hours in a porcine skin and muscle incision model. SBG004 is designed to provide extended release of bupivacaine, reducing pain without the use of opioids.
In the study, minipigs received skin and muscle incisions and were treated with SBG004, saline as a negative control, or liposomal bupivacaine as an active control in a Latin square design. Incision sensitivity was tested twice daily for seven days by a blinded assessor using von Frey filaments applied 0.5 cm from the incision.
From 0-120 hours postoperatively, the area under the curve (AUC) of mean tolerated force versus time was 84% of the maximum possible score for sites receiving SBG004 compared to 51% for liposomal bupivacaine and 23% for saline. The difference was greatest during the period 48-120 hr postoperatively, during which the average force tolerated was 147 grams for sites dosed with SBG004 compared to 74 grams for liposomal bupivacaine and 47 grams for saline. The mean force tolerated by sites receiving SBG004 was over 120 grams, or 2/3 of the maximum value tested, at all time points through 120 hours postoperatively.
Patients often experience moderate pain at rest for up to three days after surgery and moderate-to-severe pain with basic activities for five to seven days postoperatively. A local anesthetic lasting for three to five days has been viewed by many as an ideal foundation for multimodal analgesia regimens, with potential to simplify the recovery process and enable a meaningful reduction in opioid consumption.
“We are pleased with our recent findings indicating multi-day treatment of postoperative pain from SBG004,” said Dr. Derek Overstreet, Sonoran’s co-founder and Chief Executive Officer. “We look forward to bringing SBG004 into clinical development.”
About Sonoran Biosciences, Inc.
Sonoran Biosciences is a preclinical-stage pharmaceutical company leveraging its proprietary drug delivery technology to develop innovative hospital-based products for the treatment of postoperative pain and prevention of surgical site infections. Sonoran’s products are based on its proprietary SB Gel, an injectable carrier that forms a solid gel in the body, releases drugs over multiple days, and dissolves after the drugs are released. Sonoran’s lead products are SBG004, a long-acting formulation of bupivacaine, and SBG003, a fixed-dose combination of tobramycin and vancomycin for prevention of surgical site infection.